Header Logo

Connection

Elizabeth Evans to Adult

Back to Details
This is a "connection" page, showing publications Elizabeth Evans has written about Adult.
Elizabeth Evans
Connection Strength
1.899
Adult
  1. Pivovarova E, Planas Garcia BY, Friedmann PD, Stopka TJ, Santelices C, Evans EA. Collaborating With Jails to Provide Community-based Medication for Opioid Use Disorder: Qualitative Perspectives From MOUD Treatment Providers. J Addict Med. 2025 Jan-Feb 01; 19(1):95-101.
    View in: PubMed
    Score: 0.073
  2. Evans E, Jacobs M, Ellis C. Allostatic load and cognitive recall among young adults: Racial, ethnic, and sex-specific variations. J Int Neuropsychol Soc. 2024 Oct; 30(8):755-763.
    View in: PubMed
    Score: 0.072
  3. Stopka TJ, Rottapel R, Friedmann PD, Pivovarova E, Evans EA. Perceptions of extended-release buprenorphine among people who received medication for opioid use disorder in jail: a qualitative study. Addict Sci Clin Pract. 2024 Sep 12; 19(1):68.
    View in: PubMed
    Score: 0.072
  4. Evans E, Jacobs M. Diabetes and Financial Well-Being: Differential Hardship Among Vulnerable Populations. Sci Diabetes Self Manag Care. 2024 Aug; 50(4):263-274.
    View in: PubMed
    Score: 0.071
  5. Evans EA, Pivovarova E, Senthilkumar R, Rottapel RE, Stopka TJ, Santelices C, Ferguson WJ, Friedmann PD. Diversion of medications to treat opioid use disorder: Qualitative findings from formerly incarcerated adults in Massachusetts. Int J Drug Policy. 2023 Dec; 122:104252.
    View in: PubMed
    Score: 0.068
  6. Bailey A, Taylor BG, Pollack HA, Schneider JA, Evans EA. Gender identity, stimulant drug use, and criminal justice history on internalized stigma among a nationally representative sample of adults who misuse opioids. Soc Psychiatry Psychiatr Epidemiol. 2024 Feb; 59(2):305-313.
    View in: PubMed
    Score: 0.066
  7. Bailey A, Senthilkumar R, Evans EA. Correlates and Patterns in Use of Medications to Treat Opioid Use Disorder in Jail. J Addict Med. 2023 Sep-Oct 01; 17(5):568-573.
    View in: PubMed
    Score: 0.066
  8. Bailey A, Evans EA. Holyoke Early Access to Recovery and Treatment (HEART): A case study of a court-based intervention to reduce opioid overdose. J Ethn Subst Abuse. 2024 Oct-Dec; 23(4):1039-1061.
    View in: PubMed
    Score: 0.064
  9. Evans EA, Wilson D, Friedmann PD. Recidivism and mortality after in-jail buprenorphine treatment for opioid use disorder. Drug Alcohol Depend. 2022 02 01; 231:109254.
    View in: PubMed
    Score: 0.060
  10. Evans EA, Harrington C, Roose R, Lemere S, Buchanan D. Perceived Benefits and Harms of Involuntary Civil Commitment for Opioid Use Disorder. J Law Med Ethics. 2020 12; 48(4):718-734.
    View in: PubMed
    Score: 0.055
  11. Evans EA, Goldwater E, Stanek EJ, Brierley-Bowers P, Buchanan D, Whitehill JM. Prevalence and Correlates of Cannabis Use in Massachusetts after Cannabis Legalization and before Retail Sales. J Psychoactive Drugs. 2021 Apr-Jun; 53(2):158-167.
    View in: PubMed
    Score: 0.055
  12. Evans EA, Goff SL, Upchurch DM, Grella CE. Childhood adversity and mental health comorbidity in men and women with opioid use disorders. Addict Behav. 2020 03; 102:106149.
    View in: PubMed
    Score: 0.051
  13. Evans EA, Yoo C, Huang D, Saxon AJ, Hser YI. Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2?years: Results from a multisite randomized trial of adults with opioid use disorder. J Subst Abuse Treat. 2019 11; 106:19-28.
    View in: PubMed
    Score: 0.050
  14. Evans EA, Zhu Y, Yoo C, Huang D, Hser YI. Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder. Addiction. 2019 08; 114(8):1396-1404.
    View in: PubMed
    Score: 0.050
  15. Evans EA, Herman PM, Washington DL, Lorenz KA, Yuan A, Upchurch DM, Marshall N, Hamilton AB, Taylor SL. Gender Differences in Use of Complementary and Integrative Health by U.S. Military Veterans with Chronic Musculoskeletal Pain. Womens Health Issues. 2018 Sep - Oct; 28(5):379-386.
    View in: PubMed
    Score: 0.047
  16. Evans EA, Glover DL, Washington DL, Hamilton AB. Psychosocial Factors that Shape Substance Abuse and Related Mental Health of Women Military Veterans who Use Community-Based Services. Subst Use Misuse. 2018 09 19; 53(11):1878-1892.
    View in: PubMed
    Score: 0.046
  17. Evans EA, Upchurch DM, Simpson T, Hamilton AB, Hoggatt KJ. Differences by Veteran/civilian status and gender in associations between childhood adversity and alcohol and drug use disorders. Soc Psychiatry Psychiatr Epidemiol. 2018 04; 53(4):421-435.
    View in: PubMed
    Score: 0.045
  18. Evans EA, Grella CE, Washington DL, Upchurch DM. Gender and race/ethnic differences in the persistence of alcohol, drug, and poly-substance use disorders. Drug Alcohol Depend. 2017 05 01; 174:128-136.
    View in: PubMed
    Score: 0.043
  19. Evans EA, Grella CE, Upchurch DM. Gender differences in the effects of childhood adversity on alcohol, drug, and polysubstance-related disorders. Soc Psychiatry Psychiatr Epidemiol. 2017 07; 52(7):901-912.
    View in: PubMed
    Score: 0.043
  20. Evans E, Padwa H, Li L, Lin V, Hser YI. Heterogeneity of Mental Health Service Utilization and High Mental Health Service Use Among Women Eight Years After Initiating Substance Use Disorder Treatment. J Subst Abuse Treat. 2015 Dec; 59:10-9.
    View in: PubMed
    Score: 0.038
  21. Evans E, Li L, Min J, Huang D, Urada D, Liu L, Hser YI, Nosyk B. Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006-10. Addiction. 2015 Jun; 110(6):996-1005.
    View in: PubMed
    Score: 0.037
  22. Evans E, Li L, Buoncristiani S, Hser YI. Perceived neighborhood safety, recovery capital, and successful outcomes among mothers 10 years after substance abuse treatment. Subst Use Misuse. 2014 Sep; 49(11):1491-503.
    View in: PubMed
    Score: 0.035
  23. Evans E, Li L, Pierce J, Hser YI. Explaining long-term outcomes among drug dependent mothers treated in women-only versus mixed-gender programs. J Subst Abuse Treat. 2013 Sep; 45(3):293-301.
    View in: PubMed
    Score: 0.033
  24. Anglin MD, Nosyk B, Jaffe A, Urada D, Evans E. Offender diversion into substance use disorder treatment: the economic impact of California's proposition 36. Am J Public Health. 2013 Jun; 103(6):1096-102.
    View in: PubMed
    Score: 0.033
  25. Evans E, Li L, Grella C, Brecht ML, Hser YI. Developmental timing of first drug treatment and 10-year patterns of drug use. J Subst Abuse Treat. 2013 Mar; 44(3):271-9.
    View in: PubMed
    Score: 0.031
  26. Evans E, Pierce J, Li L, Rawson R, Hser YI. More alike than different: health needs, services utilization, and outcomes of Asian American and Pacific Islander (AAPI) populations treated for substance use disorders. J Ethn Subst Abuse. 2012; 11(4):318-38.
    View in: PubMed
    Score: 0.030
  27. Evans E, Huang D, Hser YI. High-risk offenders participating in court-supervised substance abuse treatment: characteristics, treatment received, and factors associated with recidivism. J Behav Health Serv Res. 2011 Oct; 38(4):510-25.
    View in: PubMed
    Score: 0.029
  28. Evans E, Anglin MD, Urada D, Yang J. Promising practices for delivery of court-supervised substance abuse treatment: perspectives from six high-performing California counties operating Proposition 36. Eval Program Plann. 2011 May; 34(2):124-34.
    View in: PubMed
    Score: 0.027
  29. Evans E, Hser YI, Huang D. Employment services utilization and outcomes among substance abusing offenders participating in California's proposition 36 drug treatment initiative. J Behav Health Serv Res. 2010 Oct; 37(4):461-76.
    View in: PubMed
    Score: 0.025
  30. Evans E, Li L, Hser YI. Client and program factors associated with dropout from court mandated drug treatment. Eval Program Plann. 2009 Aug; 32(3):204-12.
    View in: PubMed
    Score: 0.024
  31. Evans E, Li L, Hser YI. Treatment entry barriers among California's Proposition 36 offenders. J Subst Abuse Treat. 2008 Dec; 35(4):410-8.
    View in: PubMed
    Score: 0.023
  32. Hser YI, Huang D, Brecht ML, Li L, Evans E. Contrasting trajectories of heroin, cocaine, and methamphetamine use. J Addict Dis. 2008; 27(3):13-21.
    View in: PubMed
    Score: 0.023
  33. Evans E, Longshore D, Prendergast M, Urada D. Evaluation of the Substance Abuse and Crime Prevention Act: client characteristics, treatment completion and re-offending three years after implementation. J Psychoactive Drugs. 2006 Nov; Suppl 3:357-67.
    View in: PubMed
    Score: 0.021
  34. Evans E, Spear SE, Huang YC, Hser YI. Outcomes of drug and alcohol treatment programs among American Indians in California. Am J Public Health. 2006 May; 96(5):889-96.
    View in: PubMed
    Score: 0.020
  35. Michener PS, Bianchet E, Fox S, Evans EA, Friedmann PD. "Expected to happen": perspectives on post-release overdose from recently incarcerated people with opioid use disorder. Harm Reduct J. 2024 07 22; 21(1):138.
    View in: PubMed
    Score: 0.018
  36. Jacobs MM, Evans E, Ellis C. Financial Well-Being Among US Adults with Vascular Conditions: Differential Impacts Among Blacks and Hispanics. Ethn Dis. 2024 Jan; 34(1):41-48.
    View in: PubMed
    Score: 0.018
  37. Evans E, Hser YI. Pilot-testing a statewide outcome monitoring system: overview of the California Treatment Outcome Project (CALTOP). J Psychoactive Drugs. 2004 May; Suppl 2:109-14.
    View in: PubMed
    Score: 0.018
  38. Evans E, Longshore D. Evaluation of the substance abuse and crime prevention act: treatment clients and program types during the first year of implementation. J Psychoactive Drugs. 2004 May; Suppl 2:165-74.
    View in: PubMed
    Score: 0.018
  39. Bovell-Ammon BJ, Yan S, Dunn D, Evans EA, Friedmann PD, Walley AY, LaRochelle MR. Prison Buprenorphine Implementation and Postrelease Opioid Use Disorder Outcomes. JAMA Netw Open. 2024 03 04; 7(3):e242732.
    View in: PubMed
    Score: 0.017
  40. Jacobs MM, Evans E, Ellis C. Racial, ethnic, and sex disparities in the incidence and cognitive symptomology of long COVID-19. J Natl Med Assoc. 2023 Apr; 115(2):233-243.
    View in: PubMed
    Score: 0.016
  41. Hser YI, Zhu Y, Fei Z, Mooney LJ, Evans EA, Kelleghan A, Matthews A, Yoo C, Saxon AJ. Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial. Addiction. 2022 01; 117(1):151-161.
    View in: PubMed
    Score: 0.014
  42. Barnett A, Edwards K, Harper R, Evans E, Alexander D, Choudhary M, Richards G. The Association Between Autistic Traits and Disordered Eating is Moderated by Sex/Gender and Independent of Anxiety and Depression. J Autism Dev Disord. 2021 Jun; 51(6):1866-1879.
    View in: PubMed
    Score: 0.014
  43. Zhu Y, Evans EA, Mooney LJ, Saxon AJ, Kelleghan A, Yoo C, Hser YI. Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial. J Neuroimmune Pharmacol. 2018 12; 13(4):488-497.
    View in: PubMed
    Score: 0.012
  44. Krebs E, Enns B, Evans E, Urada D, Anglin MD, Rawson RA, Hser YI, Nosyk B. Cost-Effectiveness of Publicly Funded Treatment of Opioid Use Disorder in California. Ann Intern Med. 2018 01 02; 168(1):10-19.
    View in: PubMed
    Score: 0.011
  45. Wang L, Min JE, Krebs E, Evans E, Huang D, Liu L, Hser YI, Nosyk B. Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users. Int J Drug Policy. 2017 11; 49:32-40.
    View in: PubMed
    Score: 0.011
  46. Krebs E, Urada D, Evans E, Huang D, Hser YI, Nosyk B. The costs of crime during and after publicly funded treatment for opioid use disorders: a population-level study for the state of California. Addiction. 2017 May; 112(5):838-851.
    View in: PubMed
    Score: 0.011
  47. Krebs E, Min JE, Evans E, Li L, Liu L, Huang D, Urada D, Kerr T, Hser YI, Nosyk B. Estimating State Transitions for Opioid Use Disorders. Med Decis Making. 2017 07; 37(5):483-497.
    View in: PubMed
    Score: 0.011
  48. Metz VE, Sullivan MA, Jones JD, Evans E, Luba R, Vogelman J, Comer SD. Racial Differences in HIV and HCV Risk Behaviors, Transmission, and Prevention Knowledge among Non-Treatment-Seeking Individuals with Opioid Use Disorder. J Psychoactive Drugs. 2017 Jan-Mar; 49(1):59-68.
    View in: PubMed
    Score: 0.010
  49. Iacono T, Evans E, Davis A, Bhardwaj A, Turner B, Torr J, Trollor JN. Family caring of older adults with intellectual disability and coping according to loci of responsibility. Res Dev Disabil. 2016 Oct; 57:170-80.
    View in: PubMed
    Score: 0.010
  50. Hser YI, Evans E, Huang D, Weiss R, Saxon A, Carroll KM, Woody G, Liu D, Wakim P, Matthews AG, Hatch-Maillette M, Jelstrom E, Wiest K, McLaughlin P, Ling W. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addiction. 2016 Apr; 111(4):695-705.
    View in: PubMed
    Score: 0.010
  51. Nosyk B, Min JE, Evans E, Li L, Liu L, Lima VD, Wood E, Montaner JS. The Effects of Opioid Substitution Treatment and Highly Active Antiretroviral Therapy on the Cause-Specific Risk of Mortality Among HIV-Positive People Who Inject Drugs. Clin Infect Dis. 2015 Oct 01; 61(7):1157-65.
    View in: PubMed
    Score: 0.009
  52. Chitty KM, Evans E, Torr JJ, Iacono T, Brodaty H, Sachdev P, Trollor JN. Central nervous system medication use in older adults with intellectual disability: Results from the successful ageing in intellectual disability study. Aust N Z J Psychiatry. 2016 Apr; 50(4):352-62.
    View in: PubMed
    Score: 0.009
  53. Hser YI, Evans E, Grella C. Commentary on Degenhardt et?al. (2014): Regional variation in the global burden of disease attributable to opioid dependence-where do the data come from and does population size matter? Addiction. 2014 Aug; 109(8):1334-5.
    View in: PubMed
    Score: 0.009
  54. Nosyk B, Li L, Evans E, Urada D, Huang D, Wood E, Rawson R, Hser YI. Utilization and outcomes of detoxification and maintenance treatment for opioid dependence in publicly-funded facilities in California, USA: 1991-2012. Drug Alcohol Depend. 2014 Oct 01; 143:149-57.
    View in: PubMed
    Score: 0.009
  55. Gill KE, Evans E, Kayser J, Ben-David S, Messinger J, Bruder G, Malaspina D, Corcoran CM. Smell identification in individuals at clinical high risk for schizophrenia. Psychiatry Res. 2014 Dec 15; 220(1-2):201-4.
    View in: PubMed
    Score: 0.009
  56. Headley S, Germain M, Wood R, Joubert J, Milch C, Evans E, Poindexter A, Cornelius A, Brewer B, Pescatello LS, Parker B. Short-term aerobic exercise and vascular function in CKD stage 3: a randomized controlled trial. Am J Kidney Dis. 2014 Aug; 64(2):222-9.
    View in: PubMed
    Score: 0.009
  57. Nosyk B, Sun H, Evans E, Marsh DC, Anglin MD, Hser YI, Anis AH. Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment: results from a population-based retrospective cohort study. Addiction. 2012 Sep; 107(9):1621-9.
    View in: PubMed
    Score: 0.008
  58. Eby LT, Sparks TE, Evans E, Selzer JA. A qualitative examination of the positive and negative consequences associated with going tobacco-free in substance abuse treatment: the NY State experience. Nicotine Tob Res. 2012 Dec; 14(12):1407-17.
    View in: PubMed
    Score: 0.008
  59. Hser YI, Hunt SA, Evans E, Chang YJ, Messina NP. Hispanic parenting women in women-only versus mixed-gender drug treatment: a 10-year prospective study. Addict Behav. 2012 Jun; 37(6):729-35.
    View in: PubMed
    Score: 0.008
  60. Hser YI, Kagihara J, Huang D, Evans E, Messina N. Mortality among substance-using mothers in California: a 10-year prospective study. Addiction. 2012 Jan; 107(1):215-22.
    View in: PubMed
    Score: 0.007
  61. Hser YI, Li J, Jiang H, Zhang R, Du J, Zhang C, Zhang B, Evans E, Wu F, Chang YJ, Peng C, Huang D, Stitzer ML, Roll J, Zhao M. Effects of a randomized contingency management intervention on opiate abstinence and retention in methadone maintenance treatment in China. Addiction. 2011 Oct; 106(10):1801-9.
    View in: PubMed
    Score: 0.007
  62. Hser YI, Evans E, Huang D, Messina N. Long-term outcomes among drug-dependent mothers treated in women-only versus mixed-gender programs. J Subst Abuse Treat. 2011 Sep; 41(2):115-23.
    View in: PubMed
    Score: 0.007
  63. Hser YI, Evans E, Huang D, Brecht ML, Li L. Comparing the dynamic course of heroin, cocaine, and methamphetamine use over 10 years. Addict Behav. 2008 Dec; 33(12):1581-9.
    View in: PubMed
    Score: 0.006
  64. Brecht ML, Huang D, Evans E, Hser YI. Polydrug use and implications for longitudinal research: ten-year trajectories for heroin, cocaine, and methamphetamine users. Drug Alcohol Depend. 2008 Aug 01; 96(3):193-201.
    View in: PubMed
    Score: 0.006
  65. Murphy DA, Brecht ML, Herbeck D, Evans E, Huang D, Hser YI. Longitudinal HIV risk behavior among the Drug Abuse Treatment Outcome Studies (DATOS) adult sample. Eval Rev. 2008 Feb; 32(1):83-112.
    View in: PubMed
    Score: 0.006
  66. Brecht ML, Stein J, Evans E, Murphy DA, Longshore D. Predictors of intention to change HIV sexual and injection risk behaviors among heterosexual methamphetamine-using offenders in drug treatment: a test of the AIDS Risk Reduction Model. J Behav Health Serv Res. 2009 Apr; 36(2):247-66.
    View in: PubMed
    Score: 0.006
  67. Fosados R, Evans E, Hser YI. Ethnic differences in utilization of drug treatment services and outcomes among Proposition 36 offenders in California. J Subst Abuse Treat. 2007 Dec; 33(4):391-9.
    View in: PubMed
    Score: 0.005
  68. Hser YI, Evans E, Teruya C, Huang D, Anglin MD. Predictors of short-term treatment outcomes among California's Proposition 36 participants. Eval Program Plann. 2007 May; 30(2):187-96.
    View in: PubMed
    Score: 0.005
  69. Hser YI, Teruya C, Brown AH, Huang D, Evans E, Anglin MD. Impact of California's Proposition 36 on the drug treatment system: treatment capacity and displacement. Am J Public Health. 2007 Jan; 97(1):104-9.
    View in: PubMed
    Score: 0.005
  70. Hser YI, Grella C, Evans E, Huang YC. Utilization and outcomes of mental health services among patients in drug treatment. J Addict Dis. 2006; 25(1):73-85.
    View in: PubMed
    Score: 0.005
  71. Hser YI, Evans E, Huang YC. Treatment outcomes among women and men methamphetamine abusers in California. J Subst Abuse Treat. 2005 Jan; 28(1):77-85.
    View in: PubMed
    Score: 0.005
  72. Hser YI, Evans E, Huang D, Anglin DM. Relationship between drug treatment services, retention, and outcomes. Psychiatr Serv. 2004 Jul; 55(7):767-74.
    View in: PubMed
    Score: 0.004
  73. Hser YI, Teruya C, Evans EA, Longshore D, Grella C, Farabee D. Treating drug-abusing offenders. Initial findings from a five-county study on the impact of California's Proposition 36 on the treatment system and patient outcomes. Eval Rev. 2003 Oct; 27(5):479-505.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.